Publications by authors named "Delphine Bolle"

Claim this Profile
I
Impact of the relative dose intensity on survival of patients with high-risk myelodysplastic syndromes treated with Azacitidine.
Kamel Laribi, Delphine Bolle, Mustafa Alani, Habib Ghnaya, Anne Besançon

Cancer Med· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic impact of elevated pretreatment serum ferritin in patients with high-risk MDS treated with azacitidine.
Kamel Laribi, Delphine Bolle, Mustapha Alani, Habib Ghnaya, Saga Le Bourdelles

Exp Hematol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma.
Kamel Laribi, Adrien Tempescul, Habib Ghnaya, Nathalie Denizon, Anne Besançon, Delphine Bolle

Hematol Oncol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
R-CVP regimen is active in frail elderly patients aged 80 or over with diffuse large B cell lymphoma.
Kamel Laribi, Nathalie Denizon, Delphine Bolle, Catherine Truong, Anne Besançon

Ann Hematol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab is an effective and safe treatment of relapse in elderly patients with resistant warm AIHA.
Kamel Laribi, Delphine Bolle, Habib Ghnaya, Andrea Sandu, Anne Besançon

Ann Hematol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quadri-lineage disease involving nodal B-cell marginal zone lymphoma, high-grade B-cell lymphoma, Kaposi's syndrome, and acute myeloid leukemia.
Kamel Laribi, Habib Ghnaya, Pierre-Jean Mention, Hoel Rousset, Alix Baugier de Materre, Delphine Bolle

Clin Case Rep· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis